SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
- --------------------------------------------------------------------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
First Medical Group, Inc.
-------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
52481610 5
----------
(CUSIP Number)
Stephen Collier
Generale de Sante International, Ltd.
210 Euston Road
London NW1 2DA, England
Telephone: 011-44-171-419-6021
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and
Communications)
Copy to:
Paul S. Schreiber
Shearman & Sterling
599 Lexington Avenue
New York, New York 10022
Telephone: (212) 848-4000
July 10, 1997
-------------
(Date of Event which Requires Filing of this Statement)
................................................................................
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d- 1(b)(3) or (4), check the following box |_|.
Check the following box if a fee is being paid with this Statement |_|.
Exhibit Index is at Page 11
<PAGE>
CUSIP No. 52481610 5
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Generale de Sante International, Ltd.
-----------------------------------------------------------------------
-----------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
|_| (a) ------------------------------------------------------------------
|X| (b) Generale de Sante International, Ltd. disclaims membership of a
Group.
------------------------------------------------------------------
------------------------------------------------------------------
(3) SEC Use Only
-----------------------------------------------------------
-----------------------------------------------------------------------
(4) Source of Funds (See Instructions) WC
-------------------------------------
-----------------------------------------------------------------------
(5) |X| Check if Disclosure of Legal Proceedings is Required Pursuant to
Item 2(d) or 2(e).
(6) Citizenship or Place of Organization England
----------------------------------
-----------------------------------------------------------------------
Number of (7) Sole Voting Power 73,533,431
Shares -------------------
Beneficially -------------------------------------
Owned by (8) Shared Voting Power
Each -----------------
Reporting -------------------------------------
Person (9) Sole Dispositive Power 73,533,431
With --------------
-------------------------------------
(10) Shared Dispositive Power
------------
-------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person 73,533,431
----------
-----------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
<PAGE>
(13) Percent of Class Represented by Amount in Row (11) 25%
--------------------
-----------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions) CO
---------------------------
-----------------------------------------------------------------------
<PAGE>
Item 1. Security and Issuer.
The class of equity securities to which this Statement on Schedule 13D
relates is the common stock, par value $.001 per share (the "Securities"), of
First Medical Group, Inc. (the "Issuer"), a Delaware corporation, with its
principal executive offices located at 810 Seventh Avenue, New York, New York
10019.
Item 2. Identity and Background.
This statement is being filed by Generale de Sante International, Ltd.,
a company organized under the laws of England (the "Reporting Person").
The Reporting Person has its principal office at 210 Euston Road,
London NW1 2DA, England. The Reporting Person engages in the operation of
hospitals.
The directors and executive officers of the Reporting Person are set
forth on Schedule I attached hereto. Schedule I sets forth the following
information with respect to each such person:
(i) name;
(ii) business address (or residence address where indicated);
(iii) present principal occupation or employment and the name,
principal business and address of any corporation or other organization in
which such employment is conducted; and
(iv) citizenship.
During the last five years, neither the Reporting Person nor any person
named in Schedule I attached hereto has been (a) convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) or (b) a party
to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
Pursuant to an agreement and plan of merger (the "Merger Agreement"),
First Medical Corporation ("FMC") and Lehigh Management Corporation, a
wholly-owned subsidiary of The Lehigh Group Inc. ("Lehigh"), merged on July 9,
1997. Contemporaneous with the merger of FMC into Lehigh Management Corporation
(the "Merger") on July 9, 1997, Lehigh changed its name to First Medical Group,
Inc. On July 10, 1997 the
<PAGE>
Reporting Person purchased 2,717 shares of First Medical Corporation ("FMC"). Of
the 2,717 shares purchased, two hundred and fifty (250) shares are currently
being held in escrow (the "Escrow Shares") pending the resolution of a
disagreement as to the exact number of shares purchased by the Reporting Person.
It has been agreed that ownership of the Escrow Shares will vest in the
Reporting Person if the parties fail to reach an agreement. Accordingly, the
Reporting Person has beneficial ownership of the Escrow Shares.
Pursuant to the Merger Agreement, the 2,717 FMC shares purchased by the
Reporting Person on July 10, 1997 will be exchanged for 3,063,893 shares of
Common Stock of the Issuer and 281,878 shares of Preferred Stock of the Issuer.
The Reporting Person intends to convert the Preferred Stock of the Issuer into
70,469,538 shares of Common Stock of the Issuer immediately. As a result, after
its purchases on July 10, 1997 and the conversion of the Preferred Stock of the
Issuer, the Reporting Person will beneficially own 73,533,431 shares of Common
Stock of the Issuer.
The aggregate purchase price of the Securities was $4 million. The
Reporting Person obtained these funds from its working capital.
Item 4. Purpose of Transaction.
On June 11, 1996, the Reporting Person and FMC entered into a stock
subscription agreement (the "Subscription Agreement") pursuant to which the
Reporting Person became obligated to purchase for approximately $4 million a
certain percentage of FMC Preferred Stock and Common Stock upon the closing of a
transaction in which FMC became a public company. Following the closing of the
Merger between FMC and Lehigh on July 9, 1997, the Reporting Person purchased on
July 10, 1997 the required amount of stock for $4 million and on the same day
converted all FMC Preferred Stock into FMC Common Stock. Pursuant to the Merger
Agreement, the FMC stock purchased by the Reporting Person on July 10, 1997 will
be exchanged for Common Stock of the Issuer and Preferred Stock of the Issuer.
The Reporting Person intends to convert the Preferred Stock of the Issuer into
Common Stock of the Issuer.
The Reporting Person has acquired the Securities for the purpose of
making an investment in the Issuer and not with the present intention of
acquiring control of the Issuer's business.
The Reporting Person from time to time intends to review its investment
in the Issuer on the basis of various factors, including the Issuer's business,
financial condition, results of operations and prospects, general economic and
industry conditions, the securities markets in general and those for the
Issuer's securities in particular, as well as other developments and other
investment opportunities. Based upon such review, the Reporting Person will take
such actions in the future as the Reporting Person may deem appropriate in light
of the circumstances existing from time to time. If the Reporting Person
believes that further investment in the Issuer is attractive, whether because of
the market price of the
<PAGE>
Issuer's securities or otherwise, it may acquire shares of Common Stock or other
securities of the Issuer either in the open market or in privately negotiated
transactions. Similarly, depending on market and other factors, the Reporting
Person may determine to dispose of some or all of the Securities currently owned
by the Reporting Person or otherwise acquired by the Reporting Person either in
the open market or in privately negotiated transactions.
Except as set forth herein, the Reporting Person has not formulated any
plans or proposals which relate to or would result in: (a) the acquisition by
any person of additional securities of the Issuer or the disposition of
securities of the Issuer, (b) an extraordinary corporate transaction involving
the Issuer or any of its subsidiaries, (c) a sale or transfer of a material
amount of the assets of the Issuer or any of its subsidiaries, (d) any change in
the present board of directors or management of the Issuer, (e) any material
change in the Issuer's capitalization or dividend policy, (f) any other material
change in the Issuer's business or corporate structure, (g) any change in the
Issuer's charter or bylaws or other or instrument corresponding thereto or other
action which may impede the acquisition of control of the Issuer by any person,
(h) causing a class of the Issuer's securities to be deregistered or delisted,
(i) a class of equity securities of the Issuer becoming eligible for termination
of registration or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer.
As a result of its purchase of the Securities, the Reporting Person is
the beneficial owner of 73,533,431 shares of Common Stock of the Issuer,
representing approximately 25% of the currently outstanding shares of Common
Stock. The Reporting Person maintains the sole power to vote or to direct the
vote and to dispose or to direct the disposition of the Securities. No executive
officer, director, controlling person or any executive officer or director of
any corporation or other person ultimately in control of the Reporting Person
beneficially owns any shares of the Issuer.
Except as described herein, no transaction in the Common Stock of the
Issuer has been effected within the last sixty days by any person mentioned in
the above paragraph and no other person is known to have the right to receive or
the power to direct the receipt of dividends from, or the proceeds from the sale
of, the Securities.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
Pursuant to a letter from the Chairman of FMC to the Reporting Person
dated July 9, 1997, the terms of the Subscription Agreement entered into with
respect to the FMC stock remain in force with respect to the Issuer stock owned
by the Reporting Person. The Subscription Agreement provides that an Executive
Committee of the Issuer consisting of the Issuer's Chairman of the Board, the
Issuer's Chief Executive Officer and a designee of the Reporting Person shall
exist and that the Executive Committee must unanimously approve all capital
business investments which are not normal capital expenditures. The Reporting
<PAGE>
Person also has the right to designate three members of the Issuer's Board of
Directors and the right to appoint a Deputy Chief Financial Officer to be
employed by the Issuer. Thus far the Reporting Person has designated one member
of the Issuer's Board of Directors.
At any time prior to the fifth anniversary of the closing of the
Merger, the Reporting Person has the option pursuant to the Subscription
Agreement to acquire from the Issuer that number of shares that, together with
the shares of Common Stock already held by the Reporting Person, equals 51% of
the issued and outstanding Common Stock of the Issuer. The price of such shares
of Common Stock will be 110% of the average 30-day trailing market price of the
Common Stock.
Item 7. Material to Be Filed as Exhibits.
The exhibits filed with this Schedule are set forth in the Exhibit
Index.
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Statement is true, complete and
correct.
July 21, 1997 GENERALE DE SANTE INTERNATIONAL, LTD.
By:
--------------------------------
Name:
Title:
<PAGE>
Schedule I
The name and present principal occupation of each of the
executive officers and directors of the Reporting Person are set forth below.
Unless otherwise noted, each of these persons have as their business address
210 Euston Road, London NW1 2DA, England.
Principal Country of
Name Position with Reporting Person Occupation Citizenship
---- ------------------------------ ---------- -----------
Daniel Bour Director Healthcare France
Daniel Caille Director Healthcare France
<PAGE>
EXHIBIT INDEX
Exhibit No. Description Page No.
----------- ----------- --------
99 Subscription Agreement 12
Name of Subscriber: GENERALE DE SANTE INTERNATIONAL, PLC
SUBSCRIPTION AGREEMENT
First Medical Corporation
5200 Blue Lagoon Drive
Suite 250
Miami, Florida 33126
Gentlemen:
The undersigned ("Subscriber") hereby tenders this Subscription
Agreement ("Agreement") subject to the terms and conditions set forth herein. If
you are in agreement, please indicate your acceptance by executing this
Agreement in the space provided and returning one executed counterpart to
Subscriber. All references to Subscriber shall include the Subscriber's nominee.
The closing of this transaction will not occur until such time as First
Medical Corporation, a Delaware corporation (the "Issuer"), consummates a
transaction in which it becomes a public company. Accordingly, the parties agree
that all documents to be executed in connection with the transaction described
herein shall be subject to the closing of a transaction in which the Issuer
shall become a public company. Simultaneously with the closing, the Issuer
agrees to register the Common Stock (as defined below) currently owned by
Subscriber and the Common Stock purchased by Subscriber hereby as described
herein.
1. Subscription.
1.01 Subscriber hereby subscribes for and agrees to purchase a number
of shares of the Common Stock, $.01 dollar value (the "Common Stock"), of First
Medical Corporation, a Delaware corporation (the "Issuer"), equal to 10% of the
issued and outstanding Common Stock of the Issuer existing on the date of the
Closing of the transactions contemplated by this Agreement, including the shares
issued to Subscriber.
1.02 Subscriber hereby subscribes for and agrees to purchase such
amount of the 9% Series A Preferred Stock ("Preferred Stock") of the Issuer as
shall be convertible into 10% of the shares of Common Stock issued and
outstanding as at the date of issue. The Preferred Stock issued to the
Subscriber shall form a class of shares of its own. The
<PAGE>
2
Preferred Stock shall be issued to Subscriber and shall contain the terms and
conditions set forth in Exhibit "A" annexed hereto and made a part hereof by
reference, and such other terms and conditions, if any, as Issuer and Subscriber
may mutually agree upon in writing prior to the Closing of the transaction
contemplated by this Agreement. As set forth in Exhibit "A," the Preferred Stock
will pay a 9%, cumulative annual dividend, payment of which will be deferred
until the earlier of (i) the third anniversary of the Closing and (ii) the date
of conversion into Common Stock, and will be convertible into shares of Common
Stock equal to 10% of the currently issued and outstanding Common Stock on a
fully diluted basis. There will be no new issue of Common Stock during 1996.
1.03 Subscriber hereby subscribes for and agrees to purchase 49% of the
issued and outstanding shares of the Common Stock, $.01 par value (the "WHEN
Common Stock"), of WHEN Inc., a Delaware corporation and a wholly-owned
subsidiary of the Issuer (WHEN"). The WHEN Common Stock subscribed for hereby
equals 49% of the issued and outstanding WHEN Common Stock.
1.04 The purchase price for the Common Stock and Preferred Stock
purchased hereby is an aggregate of US$4,000,000. The purchase price for the
WHEN Common Stock purchased hereby is US$1,000,000.
1.05 The Issuer agrees that the proceeds from Subscriber's purchase of
the Common Stock, Preferred Stock and WHEN Common (collectively, the
"Securities") shall only be used by the Issuer for the purchase of capital
assets for WHEN and/or American Medical Clinics Development Corporation,
Limited, an Irish corporation ("AMCDC").
2. Restrictions on Transfer.
2.01 Subscriber acknowledges that it is acquiring the Securities for
its own account and for the purpose of investment and not with a view to any
distribution or resale thereof within the meaning of the Securities Act of 1933,
as amended (the "Act"), and any applicable state or other securities laws
("Other Securities Laws"). Subscriber further agrees that it will not sell,
assign or transfer any of the Securities so acquired in violation of the Act or
Other Securities Laws and acknowledges that, in taking unregistered securities,
it must continue to bear the economic risk of its investment for an indefinite
period of time because such Securities have not been registered under the Act or
Other Securities Laws. Subscriber further acknowledges that such Securities
cannot be transferred unless they are registered under the Act and Other
Securities Laws or an exemption from such registration is applicable to such
transfer.
2.02 Subscriber acknowledges that appropriate legends reflecting the
status of the Securities under the Act and Other Securities Laws will be placed
on the face of the
<PAGE>
3
certificates for such Securities at the time of their transfer and delivery,
including, without limitation, the following restrictive legend:
"The Shares represented by this certificate have been acquired directly
or indirectly from the Issuer without being registered under the
Securities Act of 1933, as amended, or any other applicable securities
laws, and are restricted securities as that term is defined under Rule
144 promulgated under the Act. These shares may not be sold, pledged,
transferred, distributed or otherwise disposed of in any manner
("Transfer") unless they are registered under the Act and any
applicable securities laws, or unless the request for Transfer is
accompanied by a favorable opinion of counsel, reasonably satisfactory
to the Issuer, stating that the Transfer will not result in a violation
of the Act or any applicable state securities laws."
2.03 Immediately following (i) a transaction in which the Issuer
becomes a public company and (ii) any conversion by Subscriber, the Issuer
agrees to register all shares of the Common Stock owned by the Subscriber under
the Securities Act of 1933, as amended (the "Act"), on a Form S-3 or other
appropriate form of registration. In addition, in the event that the Issuer
proposes to register any securities (the "Registration Shares") under the Act,
other than pursuant to a registration statement on Form S-4 or S-8, or any
successor to such forms, for the purpose of the sale or other transfer of the
Registration Shares by Issuer, Subscriber shall have the right to request the
Issuer to include its shares of Common Stock and/or Preferred Stock, as the case
may be, in such registration under the Act or any other securities laws;
provided, however, that if such registration is pursuant to an underwritten
initial public offering and in the written opinion of the Issuer's managing
underwriter for such offering, if any, the inclusion of all or a portion of the
Subscribers securities, when added to the securities being registered by the
Issuer and any selling shareholder(s) of the Issuer other than the Subscriber,
if any (the "Other Stockholders"), will exceed the maximum number of the
Issuer's securities that can be marketed at the price that could otherwise be
obtained or would otherwise materially adversely affect the offering, then the
issuer may first include in such registration all of the securities the Issuer
proposes to sell, and the number of the Subscriber's securities and the Other
Stockholders' securities that may be so included shall be allocated among the
Subscriber and the Other Stockholders pro-rata on the basis of the number of
shares that are requested to be registered by Subscriber and the Other
Stockholder(s). The parties hereto agree that the cost of registration of
Subscriber's securities shall be borne by the Issuer.
3. Covenants and Additional Agreements.
3.01 As set forth above, the shares of Preferred Stock being subscribed
for hereby shall be convertible into a number of shares of Common Stock equal to
ten percent (10%) of the Issued and outstanding Common Stock of Issuer as of the
date of issuance.
<PAGE>
4
3.02 Subscriber shall have the right to designate half of the members
of the board of directors of WHEN.
3.03 The Executive Committees of the Issuer and WHEN shall include its
Chairman of the Board, its Chief Executive Officer and a designee of Subscriber
(in the event Subscriber shall select such a designee). All capital business
investments (but not Normal capital expenditures) shall be approved only by a
unanimous vote of their respective Executive Committees. Meetings of the
Executive Committees may be held by telephone, with confirmation of votes by
fax.
3.04 At any time within three (3) years following the Closing, the
Subscriber shall have the option to put the whole of its shareholdings in WHEN
to the Issuer for the consideration of an aggregate of US$1,000,000 and a sum
equivalent to the fair market value of such shares. The fair market value of
such shareholdings shall be determined by a reputable investment banking firm to
be selected by the Issuer and the Subscriber. In the event the parties cannot
agree on an investment banker, the parties shall each select a reputable
investment banking firm and such investment banking firms shall select a third
reputable investment banking firm to determine the fair market value of the WHEN
Common Stock. The determination of the third investment banking firm shall be
binding upon the Issuer and Subscriber.
3.05 In connection with the transactions contemplated hereby,
Subscriber shall sell to the Issuer, for consideration of US$1.00, an amount
equal to one percent (1%) of the shares of AMCDC. Alain Lellouche shall become
Chairman of the Board of AMCDC.
3.06 It is understood by the Issuer and the Subscriber that all
hospital management contractual agreements will be effected through WHEN.
3.07 At any time between the second and the fifth anniversary of the
Closing, Subscriber may acquire from WHEN that number of shares of WHEN Common
Stock as may be sufficient, together with the shares acquired pursuant to this
Agreement, to provide Subscriber with 52% of the issued and outstanding WHEN
Common Stock. If Subscriber acquires 52% of the issued and outstanding common
stock of WHEN, WHEN shall enter into a management agreement with the Issuer or
its wholly-owned subsidiary or other designee, pursuant to which WHEN pays such
entity, for two years after such acquisition, an annual management fee equal to
the sum of WHEN's cost of management and a reasonable success fee to be
determined by the Issuer and the Subscriber. In the event that Subscriber
acquires the additional 3% of WHEN Common Stock, Issuer will receive from
Subscriber, at the Issuer's option, either (i) 10% of the Common Stock of FMC
that was issued at the Closing or (ii) US$3,000,000. Further, if Subscriber
acquires the additional 3% of the WHEN Common Stock, Subscriber will also have
the option to purchase at that time the remaining shares of WHEN Common Stock at
a price equal to its fair market value, as determined by one reputable
investment banking firm, to be selected by the Issuer and Subscriber. In the
event the parties cannot agree on an investment banker, the parties shall
<PAGE>
5
each select a reputable investment banking firm who shall select a third
reputable investment banking firm to determine the fair market value of the WHEN
Common Stock. The determination of the third investment banking firm shall be
binding upon the Issuer and Subscriber. If Subscriber acquires all of the WHEN
Common Stock, the management agreement described in this Section 3.07 shall
terminate.
3.08 Upon the Closing, the provision of that certain agreement dated
January 20, 1996, among the Issuer, the Subscriber and AMCDC relating to the
loan by Subscriber of US$1,200,000 shall terminate and be of no further force
and effect.
3.09 Subscriber may acquire from Issuer for US$1.00 consideration, that
number of shares of the Common Stock of AMCDC, par value of the AMCDC Common
Stock (the "AMCDC Common Stock") as may be sufficient, together with the shares
of AMCDC Common Stock already owned by Subscriber, to provide Subscriber with
52% of the issued and outstanding AMCDC Common Stock.
3.10 At any time prior to the fifth anniversary of the Closing,
Subscriber shall have the option to acquire from the Issuer, for the price of
110% of the average 30-day trailing market price thereof, that number of shares
of Common Stock of the Issuer that, together with the shares of Common Stock
already held by Subscriber, shall equal 51% of the issued and outstanding Common
Stock of the Issuer.
3.11 The Issuer and Subscriber agree that in exchange for the
Subscriber's termination of that certain option granted to Subscriber by
American Medical Clinics, Inc. ("AMC") and its successor entity American Medical
Centers Management Company, Inc., a wholly owned subsidiary of the Issuer, which
option entities the Subscriber to purchase, at any time prior to December 31,
1997, 10% of the issued and outstanding common stock of AMC, the Issuer shall
issue Subscriber a number of shares of Common Stock equal to 5% of the issued
and outstanding Common Stock of the Issuer existing immediately following the
date of the Closing of the transactions contemplated by this Agreement. Issuer
agrees that the shares of Common Stock issuable to the Subscriber pursuant to
this Section 3.11 shall not be diluted during the remainder of the year ended
December 31, 1996, absent agreement between the Issuer and the Subscriber.
3.12 It is an essential term of this Agreement that Charles Pendola
will become Chief Executive Officer of Issuer and WHEN.
3.13 Subscriber shall have the right to designate three (3) members of
the Issuer's Board of Directors. Subscriber shall also have the right to appoint
a Deputy Chief Financial Officer to be employed by the Issuer, as well as a
Deputy Managing Director of WHEN, to be employed by WHEN.
<PAGE>
6
4. Miscellaneous.
4.01 This Agreement shall be construed in accordance with and governed
by the laws of the State of Delaware.
4.02 The Closing shall take place at the offices of Patton & Boggs,
L.L.P., 2550 M Street, N.W., Washington, D.C., at 10:00 a.m. on the date
immediately following the consummation of a transaction in which the Issuer
becomes a public company or on such other date and place as Issuer and
Subscriber shall mutually agree. At the Closing of this transaction, the Issuer
shall deliver to the Subscriber duly executed stock certificates for the
Securities being subscribed for and the Subscriber shall deliver to the Issuer,
a certified or official bank check for the total subscription price set forth
above or shall wire such funds to an account designated by Issuer.
IN WITNESS WHEREOF, the parties have caused this Subscription Agreement
to be executed by the officers thereunto duly authorized on the date first set
forth below.
SUBSCRIBER:
GENERALE DE SANTE INTERNATIONAL, PLC
By: ______________________________________
Daniel Caille
Mailing Address: 4 Cornwall Terrace
London NW1 4QP ENGLAND
Date: June 11, 1996
Telephone: 011-44-071-486-1266
Fax: 011-44-071-486-9275
Accepted by:
ISSUER:
FIRST MEDICAL CORPORATION
By: ___________________
Name: ___________________
Title: ___________________
Date: ___________________
<PAGE>
EXHIBIT A
BE IT FURTHER RESOLVED, that pursuant to the authority vested in the
Board of Directors of the Corporation by its Certificate of Incorporation, the
Board of Directors does hereby provide for and authorize the issuance of an
aggregate of ______ shares of the preferred stock, par value $.01 per share, of
the Corporation, to be designated "Series A Preferred Stock" of the presently
authorized but unissued shares of preferred stock of the Corporation. The voting
powers, designations, preferences, and relative, participating, optional or
other special rights of the Series A Preferred Stock authorized hereunder and
the qualifications, limitations and restrictions of such preferences and rights
are as follows:
1. Creation of Class. There is hereby created a class of Series A
Convertible Preferred Stock, with an aggregate stated value of $2,000,000 (two
million dollars), the stated value per share being hereinafter referred to as
the ("Stated Value") and a par value of $.001 per share ("Series A Preferred
Stock"), consisting of ______ (______) shares of the authorized and unissued
shares of Series A Preferred Stock.
2. Dividends.
(a) To the extent not prohibited by Delaware law, the Board of
Directors of the Corporation shall declare and the Corporation shall pay
preferential dividends to the holders of Series A Preferred Stock accrued as
provided herein and no more dividends. Except as otherwise provided herein,
dividends on each share of Series A Preferred Stock (a "Share") shall accrue
cumulatively from and including the date of issuance at the rate of 9% of the
Stated Value of each Share per annum whether or not there are profits, surplus
or other funds of the Corporation legally available for the payment of
dividends. For purposes of this Section 2(a), the date on which the Corporation
initially issues any Share is its "date of issuance" regardless of the number of
times transfer of such Share is made on the stock records maintained by or for
the Corporation and regardless of the number of certificates that may be issued
to evidence such Share (whether by reason of transfer of such Share or for any
other reason).
(b) The Series A Preferred Stock shall be preferred as to the
payment of dividends over the shares of all existing common stock, par value
$.01 per share, of the Corporation (the "Common Stock"). Any dividends payable
on the Common Stock or any other series of preferred stock or common stock
(payable in cash or securities) shall be subordinate to dividends payable on the
Series A Preferred Stock.
(c) All dividends payable on the Preferred Stock shall accrue
and be cumulative but shall not be paid until the date of conversion of the
Series A Preferred Stock pursuant to Section 4 hereof. The dividend accrued and
payable for any period which is less than a full year shall be computed on a
pro-rata basis for the actual number of days elapsed in the period for which
payable, including the date of payment.
<PAGE>
2
(d) No interest will accrue on accumulated but unpaid
dividends until such dividends become payable as set forth in Section 2(c)
above.
(e) The Corporation agrees to take all action that may be
necessary or advisable to permit the Corporation to meet its obligations to the
holders of Series A Preferred Stock.
3. Voting Rights: Consent of Holders.
(a) Each share of Series A Preferred Stock shall be entitled
to a number of votes equal to the number of shares of Common Stock that such
share of Series A Preferred Stock is convertible into at the then existing
Conversion Rate. The existing Conversion Rate is subject to adjustment as per
the provisions of Section 4.
(b) Except as hereinafter set forth, or as provided by law or
by the rules of the National Association of Securities Dealers, Inc., the
holders of Series A Preferred Stock shall vote together with the holders of the
Common Stock (and any other class or series which may be similarly entitled to
vote with the shares of Common Stock) as one class on all matters submitted to a
vote of stockholders of the Corporation.
(c) The holders of the Series A Preferred Stock shall have the
exclusive right, voting separately as a class, to elect three (3) directors of
the Corporation at any annual meeting of the stockholders of the Corporation for
the purpose of electing directors or at such annual meeting of the holders of
the Series A Preferred Stock. The right to elect three (3) directors shall
continue, even after the Series A Preferred Stock is converted into shares of
Common Stock, until such time as the stockholders of the Corporation elect other
directors.
If the right to elect three (3) directors shall not already
have been exercised, a proper officer of the Corporation shall, upon the written
request of holders of record of 25% of the shares of the Series A Preferred
Stock then outstanding, addressed to the Secretary of the Corporation, call a
special meeting of holders of the Series A Preferred Stock for the purpose of
electing directors. Such meeting shall be held at the earliest practicable date
upon the notice required for annual meetings of stockholders at the place for
holding annual meetings of stockholders of the Corporation or a place designated
by the holders of the Series A Preferred Stock. If such meeting shall not be
called by the proper officers of the Corporation within 30 days after the
personal service of such written request upon the Secretary of the Corporation,
or within 30 days after mailing the same within the United States, by registered
mail, addressed to the Secretary of the Corporation at its principal office
(such mailing to be evidenced by the registry receipt issued by the postal
authorities), then the holders of record of 25% of the shares of the Series A
Preferred Stock then outstanding may designate in writing a holder of the Series
A Preferred Stock to call such meeting at the expense of the Corporation, and
such meeting may be called by such person so designated upon the notice required
for annual meetings of stockholders and shall be held at the same
<PAGE>
3
place as is elsewhere provided in this Section 3(c). Any holder of the Series A
Preferred Stock entitled to vote at such meeting shall have access to the stock
books of the Corporation for the purpose of causing a meeting of stockholders to
be called pursuant to the provisions of this Section 3(c). Notwithstanding the
provisions of this Section 3(c), however, no such special meeting shall be
called during a period within 60 days immediately preceding the date fixed for
the next annual meeting of stockholders.
At any meeting held for the purpose of electing directors at
which the holders of the Series A Preferred Stock shall have the right to elect
directors as provided herein, the presence in person or by proxy of the holders
of a majority of the then outstanding shares of the Series A Preferred Stock
shall be required and be sufficient to constitute a quorum of such class for the
election of directors by such class. At any such meeting or adjournment thereof
(i) the absence of a quorum of the holders of the Series A Preferred Stock
having such right shall not prevent the election of directors other than those
to be elected by the holders of the Series A Preferred Stock and the absence of
a quorum or quorums of the holders of capital stock entitled to elect such other
directors shall not prevent the election of directors to be elected by the
holders of the Series A Preferred Stock entitled to elect such directors and
(ii) in the absence of a quorum of the holders of any class of stock entitled to
vote for the election of directors, a majority of the holders of such class
present in person or by proxy shall have the power to adjourn the meeting for
the election of directors which the holders of such class are entitled to elect,
from time to time, without notice (except as required by law) other than
announcement at the meeting, until a quorum shall be present.
The term of office of all directors elected by the holders of
the Series A Preferred Stock pursuant to this Section 3(c) in office at any time
when the aforesaid voting right is vested in the holders of the Series A
Preferred Stock shall terminate upon the election of their successors at any
meeting of stockholders for the purpose of electing directors (it being
understood that such successors shall be elected by the holders of the Series A
Preferred Stock).
(d) The consenting votes of the record holders of 100% of the
outstanding shares of Series A Preferred Stock, voting separately as a class,
shall be required in the event the Corporation seeks to adversely affect the
rights, preferences or privileges of the holders thereof, and in particular,
without limitation, in the event the Corporation:
(i) increases the authorized amount of Series A Preferred
Stock;
(ii) authorizes or issues shares of any class or series of
stock not expressly authorized herein having any preference or priority
as to dividends, assets or other rights superior to or on a parity with
any such preference or priority of the Series A Preferred Stock, or
authorizes or issues shares of stock of any class or any bonds,
debentures, notes or other obligations convertible into or exchangeable
for, or having options to purchase, any shares of stock of the
Corporation having any
<PAGE>
4
preference or priority as to dividends, assets or other rights superior
to or on a parity with any such preference or priority of the Series A
Preferred Stock;
(iii) reclassifies any class or series of any junior stock
into shares of stock on a parity with or senior to the Series A
Preferred Stock, or reclassify any class or series of parity stock into
senior stock;
(iv) effects any material change of the principal business of
the Corporation, which is currently providing services related to the
healthcare industry or
(v) seeks to change the Stated Value, the dividend rate or,
the optional conversion provisions contained in Section 4 hereof.
All shares issued to Subscriber shall be free of any and all options, liens,
charges, encumbrances or other third party rights at and as of the date of
issue, conversion or upon an exchange of shares in connection with a merger
transaction.
4. Conversion. The holders of shares of Series A Preferred Stock shall
have conversion rights as follows:
(a) Mandatory Conversion. At the close of business on third
anniversary of the closing date (the "Mandatory Conversion Date"), all
outstanding shares of Series A Preferred Stock shall automatically convert into
10% of the issued and outstanding shares of Common Stock of the Corporation on a
fully diluted basis (as such shares may be constituted on the Mandatory
Conversion Date) such number of Common Stock as shall require to be given for
each Series A Preferred Stock so as to convert the latter into 10% of the Common
Stock at the date of issue, subject to adjustments as provided for herein, being
the conversion rate (as adjusted from time to time pursuant hereto, the
"Conversion Rate"). The Corporation shall provide notice of the conversion of
the shares of Series A Preferred Stock to holders of record of the shares of
Series A Preferred Stock not less than thirty (30) nor more than sixty (60) days
prior to the Mandatory Conversion Date. Notice of the conversion shall state the
Mandatory Conversion Date; the then effective Conversion Rate; and the place or
places where certificates for such shares of Series A Preferred Stock are to be
surrendered for conversion. Any such notice shall be provided by fax and mail,
sent to all the holders of record of the shares of Series A Preferred Stock at
each such holder's address as it appears on the stock register of the
Corporation, first class postage prepaid; provided, however, that failure to
give such notice or any defect therein will not affect the validity of the
proceeding for conversion of all outstanding shares of Series A Preferred Stock.
The holder of a share or shares of Series A Preferred Stock shall deliver to the
Corporation on or prior to the Mandatory Conversion Date during regular business
hours, at such place as may have been designated by the Corporation, the
certificate or certificates for the shares to be converted, duly endorsed or
assigned in blank or to the Corporation (if required by it), accompanied by
written notice stating the name or names (with address) in which the certificate
or certificates
<PAGE>
5
for Common Stock are to be issued. Conversion shall be deemed to have been
effected on the Mandatory Conversion Date notwithstanding the date on which such
certificate or certificates are actually received by the Corporation. As
promptly as practicable after the Mandatory Conversion Date, the Corporation
shall issue and deliver to or upon the written order of such holder, a
certificate or certificates for the number of full shares of Common Stock to
which such holder is entitled and such adjustment in respect of any fraction of
a share as provided in subparagraph (d) below. The person in whose name the
certificate or certificates for Common Stock are to be issued shall be deemed to
have become a holder of Common Stock of record on the Mandatory Conversion Date.
(b) Each holder of a share of Series A Preferred Stock shall
have the right, at any time, to convert such share into fully paid and
nonassessable shares of Common Stock, at the Conversion Rate.
(c) The Corporation shall not be required, in connection with
any conversion of shares of Series A Preferred Stock to issue a fraction of a
share of its Common Stock, but in lieu thereof the Corporation shall make a cash
payment (calculated to the nearest cent) equal to such fraction multiplied by
the market price of the Common Stock on the trading day prior to conversion.
(d) Any holder of shares of Series A Preferred Stock compelled
or electing to convert such shares into Common Stock shall surrender the
certificate or certificates for such shares at the office of the Corporation (or
at such other place as the Corporation may designate by notice to the holders of
shares of Series A Preferred Stock) during regular business hours, duly endorsed
to the Corporation or in blank, or accompanied by instruments of transfer to the
Corporation in blank, in form satisfactory to the Corporation and, in the case
of an optional conversion, shall give written notice to the Corporation at such
office that such holder elects to convert such shares of Series A Preferred
Stock. The Corporation shall, as soon as practicable after such deposit of
certificates for shares of this Series, accompanied by the written notice above
prescribed, issue and deliver to the holder for whose account such shares were
surrendered, or to his nominee at such address communicated to the Corporation,
certificates representing the number of shares of Common Stock and the cash, if
any, to which such holder is entitled upon such conversion.
(e) In the case of an optional conversion, conversion shall be
deemed to have been made as of the date of surrender of certificates for the
shares of Series A Preferred Stock to be converted, and the giving of written
notice as hereinabove provided; and the person entitled to receive the Common
Stock issuable upon such conversion shall be treated for all purposes as the
record holder of such Common Stock on such date. The Corporation shall not be
required to deliver certificates for shares of its Common Stock while the stock
transfer books for such stock or for this Series A Preferred Stock are duly
closed for any purpose, but certificates for shares of Common Stock shall be
issued and delivered as soon as practicable after the opening of such books.
<PAGE>
6
(f) The conversion rate shall be adjusted from time to time as
follows:
(i) In case the Corporation shall (a) pay a dividend or make a
distribution in shares of its capital stock (whether shares of Common
Stock or of capital stock of any other class) to holders of Common
Stock, (b) subdivide its outstanding shares of Common Stock, (c)
combine its outstanding shares of Common Stock into a smaller number of
shares, or (d) issue by reclassification of its shares of Common Stock
any shares of capital stock of the Corporation, the conversion right
and the conversion rate in effect immediately prior to such action
shall be adjusted so that the holder of any shares of this Series A
Preferred Stock thereafter surrendered for conversion shall be entitled
to receive the number of shares of capital stock of the Corporation
which such holder would have owned immediately following such action
and such shares of this Series A Preferred Stock been converted
immediately prior thereto. An adjustment made pursuant to this
subparagraph shall become effective retroactively immediately after the
record date in the case of a dividend or distribution and shall become
effective immediately after the effective date in the case of a
subdivision, combination or reclassification. If, as a result of an
adjustment made pursuant to this Section, the holder of any shares of
this Series thereafter surrendered for conversion shall become entitled
to receive shares of two or more classes of capital stock of the
Corporation, the Board of Directors (whose determination shall be
conclusive) shall determine the allocation of the adjusted conversion
rate between or among shares of such classes of capital stock.
(ii) In case the Corporation shall issue rights or warrants to
all holders of its Common Stock entitling them to subscribe for or
purchase shares of Common Stock at a price per share less than the
market price of the Common Stock on the record date referred to below,
the conversion rate shall be adjusted so that it shall equal the rate
determined by multiplying the conversion rate in effect immediately
prior to the date of issuance of such rights or warrants by a fraction,
the numerator of which shall be the number of shares of Common Stock
outstanding on the date of issuance of such rights or warrants plus the
number of additional shares of Common Stock offered for subscription or
purchase, and the denominator of which shall be the number of shares of
Common Stock outstanding on the date of issuance of such rights or
warrants plus the number of shares that the aggregate offering price of
the total number of shares so offered would purchase at such current
market price. Such adjustment shall become effective retroactively
immediately after the record date for the determination of stockholders
entitled to receive such rights or warrants.
(iii) In case the Corporation shall distribute to all holders
of its Common Stock evidences of its indebtedness or assets (exclusive
of any cash dividend paid from retained earnings of the Corporation) or
rights or warrants to subscribe to securities of the Corporation
(excluding those hereinabove described), then in each such case the
conversion rate shall be adjusted so that it shall equal the rate
determined by multiplying the conversion rate in effect immediately
prior to the date
<PAGE>
7
of such distribution by a fraction, the numerator of which shall be the
current market price of the Common Stock on the record date referred to
below, and the denominator of which shall be such current market price
of the Common Stock less the then fair market value (as determined by
the Board of Directors of the Corporation, whose determination shall be
conclusive) of the portion of the assets or evidences of indebtedness
so distributed or of such subscription rights or warrants applicable to
one share of Common Stock. Such adjustment shall become effective
retroactively immediately after the record date for the determination
of stockholders entitled to receive such distribution.
(iv) Notwithstanding the foregoing, the Corporation shall not
be required to make any adjustment of the conversion rate unless such
adjustment would require an increase or decrease of at least 1% in such
rate. Any lesser adjustment shall be carried forward and shall be made
at the time of and together with the next subsequent adjustment which,
together with any adjustment or adjustments so carried forward, shall
amount to an increase or decrease of at least 1% in such rate.
(v) Whenever an adjustment in the conversion rate is required,
the Corporation shall forthwith place on file with its Secretary a
statement signed by its President or a Vice President and by its
Secretary or Treasurer or one of its Assistant Secretaries or Assistant
Treasurers, stating the adjusted conversion rate determined as provided
herein. Such statements shall set forth in reasonable detail such facts
as shall be necessary to show the reason and the manner of computing
such adjustment. Promptly after the adjustment of the conversion rate,
the Corporation shall mail a notice thereof to each holder of shares of
Series A, Preferred Stock.
(vi) In case of either (a) any consolidation or merger to
which the Corporation is a party, other than a merger or consolidation
in which the Corporation is the surviving or continuing corporation and
which does not result in any reclassification of, or change (other than
a change in par value or from par value to no par value or from no par
value to par value, or as a result of a subdivision or combination) in,
outstanding shares of Common Stock, or (b) any sale or conveyance to
another corporation of all or substantially all of the assets of the
Corporation, then the Corporation, or such successor corporation, as
the case may be, shall make appropriate provision so that the holder of
each of Series A Preferred Stock then outstanding shall have the right
to convert such shares of Series A Preferred Stock into the kind and
amount of shares or other securities and property receivable upon such
consolidation, merger, sale or conveyance by a holder of the number of
shares of Common Stock into which such shares of Series A Preferred
Stock might have been converted immediately prior to consolidation,
merger, sale or conveyance, subject to adjustments which shall be as
nearly equivalent as may be practicable to the adjustments provided for
hereunder. The provisions of this Section shall apply similarly to
successive consolidations, mergers, sales or conveyances.
<PAGE>
8
(vii) The Corporation shall take all necessary action to cause
any shares of Series A Preferred Stock which shall at any time have
been converted to resume the status of authorized but unissued shares
of Series A Preferred Stock, without designation as to series, until
such shares are once more designated as part of a particular series by
the Board of Directors. The Corporation shall at all times reserve and
keep available out of its authorized but unissued stock, for the
purpose of effecting the conversion of the shares of this Series, such
number of its duly authorized shares of Common Stock as shall from time
to time be sufficient to effect the conversion of all outstanding
shares of this Series; provided, however, that nothing contained herein
shall preclude the Corporation from satisfying its obligations in
respect of the conversion of the shares by delivery of purchased shares
of Common Stock which are held in the treasury of the Corporation.
(viii) If any shares of Common Stock required to be reserved
for purposes of conversion of shares of Series A Preferred Stock
hereunder require registration with or approval of any governmental
authority before such shares may be issued upon conversion, the
Corporation shall cause such shares to be duly registered or approved,
as the case may be. The Corporation will endeavor to list the shares of
Common Stock required to be delivered upon conversion of shares of this
Series prior to such delivery upon each national securities exchange
upon which the outstanding Common Stock is listed at the time of such
delivery.
(ix) The Corporation shall pay any and all issue or transfer
taxes that may be payable in respect of any issue or delivery of shares
of Common Stock on conversion of shares of Series A Preferred Stock
pursuant hereto.
(x) Before taking any action that would result in the
conversion rate being less than the then par value of the Common Stock,
the Corporation shall take any corporate action which may, in the
opinion of its counsel, be necessary in order that the Corporation may
validly and legally issue fully paid and nonassessable shares of Common
Stock.
(xi) As used herein, the term "market price" shall mean the
closing or last sales price for the security on the principal exchange
on which the security is then traded or the NASDAQ National Market, as
the case may be, or if not so traded, the average of the closing bid
and asked price on NASDAQ, or if not so traded, the average of the high
or low bid prices as reported by the National Quotation Bureau,
Incorporated. If no quotation is available for an applicable conversion
record date, the quotation used shall be that for the most recent
trading day prior to the record date of which a quotation is available.
If the Common Stock, at the time of the applicable record date, is not
publicly traded, the "market price" shall be fixed by the Board of
Directors of the Corporation, whose determination, in the absence of
fraud or bad faith, shall be conclusive. As used herein, the term
"trading day" shall be a
<PAGE>
9
day on which the principal securities exchange on which the Common
Stock is traded, is open for business.
5. Liquidation, Dissolution, Winding Up. In the event of any
liquidation, dissolution or winding up of the affairs of the Corporation, either
voluntarily or involuntarily, the amount that shall be paid to the holder of
each share of Series A Preferred Stock (the "liquidation value" of such shares)
shall be the fixed amount of the Stated Value for each such share and the
additional sum representing declared but unpaid dividends thereon, if any.
Neither the merger or consolidation of the Corporation, nor the sale, lease or
conveyance of all or part of its assets, shall be deemed to be a liquidation,
dissolution or winding up of the affairs of the Corporation, either voluntarily
or involuntarily, within the meaning of this section.
6. Preferential Rank. All shares of Common Stock shall be of junior
rank in respect of the preferences as to dividend, distributions and payments
upon the liquidation, dissolution or winding up of the Corporation to all shares
of Series A Preferred Stock. The rights of the shares of Common Stock shall be
subject to the preferences and rights of the Series A Preferred Stock.
7. Reacquired Shares. Any shares of Series A Preferred Stock that have
been issued and subsequently reacquired by the Corporation or redeemed or
purchased or otherwise acquired by the Corporation in any manner whatsoever
shall be retired and canceled promptly after the acquisition thereof. All such
Shares upon their cancellation shall become authorized but unissued shares of
the preferred stock, par value $.01 per share, of the Corporation and may be
redeemed as part of a new series of preferred stock of the Corporation to be
created by resolution or resolutions of the Board of Directors, subject to the
conditions and restrictions on issuance set forth in the Corporation's
Certificate of Incorporation.
